Jonathan A. Ledermann

Medicine · Health Sciences

89h-index49.0kcitations499works13.22yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(321), PARP inhibition in cancer therapy(174), Endometrial and Cervical Cancer Treatments(86), BRCA gene mutations in cancer(72), Intraperitoneal and Appendiceal Malignancies(54)

Publications492 total

Impact of KELIM chemosensitivity and interval cytoreduction on survival outcomes from neoadjuvant weekly dose-dense paclitaxel +/- bevacizumab : pooled analysis of ICON8 and ICON8B phase III trials.
International Journal of Gynecological Cancer·2026
ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysis
International Journal of Gynecological Cancer·2026
Long-term outcomes in patients with platinum-sensitive recurrent ovarian cancer receiving ≥ 2 year duration of maintenance PARP inhibitor therapy
International Journal of Gynecological Cancer·2026
Swiss-GO-08/OV-PRECISION: A randomized controlled swiss trial examining the benefit of multimodal guided therapy in ovarian cancer
International Journal of Gynecological Cancer·2026
The PARP inhibitor/immunotherapy paradox in advanced ovarian cancer: positive endpoints, perplexing interpretations
Annals of Oncology·2025
PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer
JAMA Network Open·2025· 3 citedOpen Access
POST-OPERATIVE HORMONAL THERAPY VERSUS CHEMOTHERAPY IN STAGE II-IV LOW-GRADE SEROUS OVARIAN CARCINOMA: A TWO-CENTRE RETROSPECTIVE ANALYSIS
International Journal of Gynecological Cancer·2025
Multiband optical variability on diverse timescales of the blazar Ton 599 from 2011 to 2023
Astronomy and Astrophysics·2025Open Access
1131P Upgrading the performance of ECOG performance status in recurrent ovarian cancer (ECOG+)
Annals of Oncology·2025
Mechanisms of drug resistance: PARP inhibitors, antibody-drug-conjugates, and immunotherapy
International Journal of Gynecological Cancer·2025· 1 citedOpen Access
INTERLACE: not a new standard for cervical cancer chemoradiation – Authors' reply
The Lancet·2025Open Access
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025
The Lancet Oncology·2025· 91 citedOpen Access
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial
European Journal of Cancer·2025· 4 citedOpen Access
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial
Gynecologic Oncology·2025· 2 citedOpen Access
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
Gynecologic Oncology·2025· 5 cited
Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial
European Journal of Cancer·2025· 4 citedOpen Access
Induction Chemotherapy Followed by Standard Chemoradiotherapy Versus Standard Chemoradiotherapy Alone in Patients With Locally Advanced Cervical Cancer (GCIG INTERLACE): An International, Multicentre, Randomised Phase 3 Trial
Obstetrical & Gynecological Survey·2025
The Incidence Of Breast Cancer In Ovarian Cancer Patients With BRCA Mutations: A Multicentre Retrospective Cohort Study.
International Journal of Gynecological Cancer·2025
Controversies in the organization and structure of management for rare tumors
International Journal of Gynecological Cancer·2025· 1 cited
Controversies in the management of rare gynecologic cancers
International Journal of Gynecological Cancer·2025
page 1 of 25Next →

Frequent Co-authors

Nicoletta Colombo(22), Ignace Vergote(17), Antonio González-Martı́n(15), Amit M. Oza(11), Domenica Lorusso(11), Christian Marth(11), Michael Friedländer(11), Susana Banerjee(11), Mansoor Raza Mirza(10), Denis Querleu(10), Carien L. Creutzberg(10), Sandro Pignata(10), Cristiana Sessa(10), Jalid Sehouli(9), Philipp Harter(9), Clare L. Scott(9), Remi A. Nout(9), Iain A. McNeish(9), Charlie Gourley(8), Gordon Rustin(8)